PipeBio ApS

Based in Denmark, PipeBio ApS specializes in bioinformatics, providing a cloud-based platform for the analysis of antibody and peptide sequences, enhancing research and development in biopharmaceuticals. Founded in 2020 and headquartered in Aarhus, Denmark, PipeBio ApS focuses on bioinformatics solutions for antibody discovery and development. The company has successfully completed one funding deal, further establishing its operational footprint in the biotechnology sector. The recent acquisition by Benchling, Inc.

on October 20, 2024, marks a significant milestone in the company’s journey. PipeBio provides a cloud-based bioinformatics software platform designed for the analysis of various antibody and peptide sequences, including BCR, TCR, VHH, and scFv. This solution automates workflows for identifying candidate sequences from extensive NGS antibody repertoires, facilitating processes such as hybridoma sequencing, clonal expansion during biopanning experiments, and assessing antibody developability. The platform allows users to store and manage antibody sequences in a centralized database, linking them with metadata such as target specificity and binding affinity.

PipeBio's offerings are tailored for researchers and biopharmaceutical companies engaged in antibody discovery and development, primarily serving customers in the United States and European markets, where there is a significant demand for innovative biotherapeutics. PipeBio generates revenue primarily through subscription-based access to its bioinformatics solutions, which may include tiered pricing plans based on the level of features and data capacity. Clients, typically bioscience companies and research institutions, enter into agreements that facilitate ongoing access to the software, often complemented by professional services such as training and support. As firms increasingly rely on automated solutions for antibody and peptide discovery, the demand for PipeBio's offerings is expected to grow, allowing for consistent revenue streams from both existing and new customers.

The integration capabilities with systems like ELN and LIMS enhance the value proposition of their services, fostering long-term partnerships with clients seeking to optimize their biologics discovery workflows. Following its recent acquisition by Benchling, Inc. in October 2024, PipeBio plans to leverage new resources for product development and expand its market presence. The company aims to enhance its current offerings with new features and tools designed for antibody and peptide discovery, targeting a launch timeline within the upcoming year.

Additionally, PipeBio is exploring expansion into Asian markets, capitalizing on the growing demand for biotherapeutic solutions, with plans set to initiate operations by mid-2025. The strategic use of funds from the acquisition deal will support these initiatives and facilitate broader engagement with potential clients in emerging regions.